'I was too fat for NHS cancer surgery appointment'
A woman diagnosed with inflammatory breast cancer has told the BBC the NHS said her Body Mass Index (BMI) was too high to discuss surgery.Rosemarie Winfield, 44, from Hailsham in East Sussex, was diagnosed in 2024 and is currently undergoing treatment. She had been referred to the Queen Victoria Hospital (QVH) in East Grinstead to discuss reconstruction options if she were to decide on a mastectomy but said she was "essentially... too fat for them even to speak to me".The hospital trust said it aimed to "treat every patient with respect and empathy" and was sorry Ms Winfield felt disappointed.
Ms Winfield, who has a BMI of 36, said: "My expectation was that QVH was going to talk to me about what the reconstruction options were."However, she said she was told "we can't see you because your BMI is too high... and obviously that was upsetting."Inflammatory breast cancer is a rare type of cancer, which blocks the lymph vessels in the breasts, causing them to become red and inflamed.It "can develop quickly" and "in general, the outlook for this type of cancer is worse than for other types of breast cancer", according to Cancer Research.Ms Winfield said: "It's quite a rare and serious type of cancer - there's a 50% chance I'll be here in five years."She said if patients were overweight "then help them to lose weight, give them that support if they want a reconstruction rather than just cut off options for people".
'This is a disgrace'
Ms Winfield received an apology after complaining to QVH but said: "Every patient should be treated with kindness and empathy within the NHS."They treated me like a subhuman based on an unscientific BMI number. This is a disgrace."
Louise Grimsdell, senior clinical nurse specialist at Breast Cancer Now, said: "Women with breast cancer need to be provided with clear information, and have all suitable options discussed with them."Some people may be advised not to have breast reconstruction, and this may be for a number of reasons, including having a high body mass index (BMI). "Women who are advised not to have reconstruction, or to have delayed reconstruction due to their BMI, should receive clear explanations about the reasons for this."
A spokesperson for QVH said: "We aim to treat every patient with respect and empathy and we are sorry that Ms Winfield felt disappointed."To undergo complex breast reconstruction at QVH, patients need to fulfil certain medical criteria, including being non-smokers and having a body mass index (BMI) below 35. "This is because post-operative complications increase dramatically for patients with a higher BMI, which can also compromise further cancer treatment such as chemo or radiotherapy."The hospital said a safer option would be to have mastectomy surgery, take time to recover, and then consider breast reconstruction as a delayed procedure. The hospital also said it offered a "prehabilitation programme" to help patients lose weight and improve fitness prior to elective surgery.It said it was investigating Miss Winfield's experience "fully" and had offered her an appointment to discuss her concerns with a breast reconstruction consultant, or, if she preferred, an urgent referral to another hospital for a second opinion.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
32 minutes ago
- Scottish Sun
Ozempic-like fat jabs taken by millions linked to 181 cases of killer side effect and 5 deaths, health officials warn
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FAT jabs have been linked to hundreds of people falling ill with a life-threatening illness and 10 deaths, the UK's drug watchdog has warned. Brits have reported falling seriously ill with pancreatitis, a condition where the pancreas becomes inflamed, after taking popular weight loss and diabetes drugs. Sign up for Scottish Sun newsletter Sign up 1 Fresh figures from the UK's medicines regulator reveal more than 560 suspected cases of the illness linked to so-called GLP-1 drugs, which include Mounjaro, Wegovy and Ozempic. At least ten of these cases were fatal, although it's not clear the drugs were directly to blame. The Medicines and Healthcare products Regulatory Agency (MHRA) says the reports have triggered a new investigation into whether people's genes could make them more vulnerable to side effects. Since the drugs were approved for use, 181 cases of pancreatitis have been linked to tirzepatide, the active ingredient in Mounjaro, including five deaths. Another 113 cases have been linked to semaglutide, found in Wegovy and Ozempic, with one fatality. Liraglutide, another weight loss jab, has been tied to 116 suspected cases and one death. Exenatide has been linked to 101 cases, including three deaths, while dulaglutide and lixisenatide have been associated with 63 cases in total, with no known fatalities. The MHRA said these are suspected adverse reactions reported by patients, carers or doctors and there is no firm evidence that the jabs directly caused the deaths. Pancreatitis can also develop in people who don't take these drugs, and is often triggered by gallstones or alcohol. However, regulators believe there could be a genetic link in some patients, and are now launching a study to investigate. The Yellow Card Biobank project, set up with Genomics England, is calling on anyone who has been admitted to hospital with pancreatitis while taking a GLP-1 drug to come forward and provide a saliva sample for analysis. Julia Hartley-Brewer slams government plan for NHS to offer free 'fat jabs' to tackle obesity crisis Dr Alison Cave, MHRA's chief safety officer, said: "Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. "Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions - enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. "To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. "Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety." Pancreatitis is a painful condition that causes severe stomach pain, vomiting and fever. Acute cases usually clear up with fluids and oxygen in hospital, but around five per cent are fatal or cause lasting damage. Despite the risks, experts say the drugs are still safe and effective for most patients. They help control blood sugar, trigger rapid weight loss, and cut the risk of dying from heart disease by around a fifth in people with obesity or type 2 diabetes. Roughly 1.5million people in the UK are now taking GLP-1 drugs, which have been hailed by some as game-changers in the fight against obesity. But health officials warn they are not a silver bullet and can come with side effects, most commonly nausea, constipation and diarrhoea. The MHRA also recently warned that Mounjaro could reduce the effectiveness of the contraceptive pill in some patients. Professor Matt Brown, chief scientific officer of Genomics England, said: "GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. "We believe there is real potential to minimise these with many adverse reactions having a genetic cause. "This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system."
The Guardian
2 hours ago
- The Guardian
As an NHS GP, I can now prescribe weight-loss jabs – but a quick fix for obesity is not what we need
A medicine that takes away your appetite by making you feel full and a bit nauseous doesn't sound very attractive, but it is a price many people are ready to pay for the chance to lose weight. Although widely available privately, until this week only doctors in specialist clinics were allowed to prescribe tirzepatide (Mounjaro) to treat obesity on the NHS and it was almost impossible for GPs to get their patients into these clinics. People up and down England will no doubt rejoice at the news that their own doctor can now prescribe it. Any celebrations may be premature, as the criteria for prescription in the first phase of the rollout are so tightly drawn that few patients will qualify. You need a body mass index (BMI) of more than 40, which corresponds to a weight of 102kg (16st) for a woman of average height or 123kg (more than 19st) for a man. (The BMI criterion is slightly lower if you come from a high-risk group.) To be eligible, patients need to be not just at risk of complications from their obesity, but already suffering from them. They must have existing diagnoses of four out of five specific conditions: type 2 diabetes, high blood pressure, abnormal levels of fats in the blood (dyslipidaemia), obstructive sleep apnoea and damage to blood vessels. Individually, all of these conditions are fairly common, and they are more likely if you are obese. However, in our GP practice of 12,500 patients, we have identified only two who meet these criteria. Anticipating a rush of inquiries, we have asked our reception staff to tell patients that we will contact them if they qualify. In the second phase of the rollout, expected next summer, the BMI threshold will be lowered, although as the list of conditions will stay the same, it seems unlikely many more of my patients will qualify. I have some patients who are really stuck with very severe obesity, with a BMI of more than 50, who I think would benefit from this medication, yet I cannot prescribe it as they do not have the specified diagnoses. One of the reasons for the slow pace of the rollout mandated by NHS England is probably a fear of overwhelming GP services. Six hours of training is advised before we start prescribing, and patients should be seen monthly and monitored for adverse effects as the dose is increased, and then every six months. As the criteria relax, and the number of eligible patients expands, this will add up to a lot of extra appointments. Along with the injections, patients should also have 'wraparound care', which will provide diet and exercise advice. We are waiting to hear from our integrated care board about exactly how this will be provided to our patients, but the dietary advice is important. Many people who are obese are nevertheless malnourished as the food they eat is often high in fat and sugar and low in essential nutrients. If, in response to appetite suppression, they eat very much less of the same low-quality food, they may run into significant problems with lack of protein, vitamins and minerals. Dehydration may also be a problem as thirst is reduced as well as hunger. Rapid weight reduction causes loss of bone and muscle mass as well as fat, so exercise is needed to prevent frailty. Tirzepatide is not cheap: at the maximum dose, it costs £122 a patient a month, or £1,464 a year. This could be considered a bargain if you compare it with the cost of treating obesity-related conditions, and we should factor in the improvements in quality of life that achieving a healthy weight will bring. However, there are big questions to answer around how long people should use weight-loss drugs for, and what happens when they stop. Rebound weight gain is almost universal after a period of dieting but it appears to be even more rapid after taking drugs such as tirzepatide; one study has found that patients can expect to return to their original weight within under two years of stopping. This feels inevitable, as much of dieting is learning to change your response to your body's signals of hunger; if you've been taking a drug that abolishes those signals, then when you stop and your appetite returns, you are likely to respond exactly as you did in the past. At a population level, I worry that by concentrating on this technical, pharmaceutical fix to our obesity problem, we are heading down the wrong path. More than a quarter of the adult population in England is obese, and medicating them all in perpetuity surely cannot be the answer. If the government is serious about its much-heralded shift from treatment to prevention, we need bolder and more imaginative plans to tackle obesity. We need restrictions on the availability of calorie-dense, nutritionally poor, fast food. Taxing sugar and fat would be one way of altering the nation's diet, and we should also look at the quality of school meals. Beyond food regulation, we need to buy back school playing fields, offer opportunities to exercise for free, and encourage active transport by making pavements pleasant and cycle routes safe. The current obesity crisis arises from a complex mix of social and commercial determinants of health and these are not problems that can be fixed with a simple injection. Helen Salisbury is a GP in Oxford
Wales Online
3 hours ago
- Wales Online
Surge in people getting tested after Dermot Murnaghan cancer news
Surge in people getting tested after Dermot Murnaghan cancer news There have been a number of recent high-profile cases of prostate cancer, and a number of well-known people have died after contracting the illness Sky News gears up to provide special coverage of the US Election with Dermot Murnaghan Thousands of men have ordered a cancer test after TV presenter Dermot Murnaghan announced he has cancer. Former Sky News presenter Murnaghan has announced he has stage four prostate cancer. The broadcaster, 67, who spent more than 15 years at the news channel before his departure in 2023, said he is 'responding positively' to treatment in a post to X on Monday. 'Some personal news… I've been diagnosed with Stage IV advanced prostate cancer', he said. 'I'm fortunate to have a simply outstanding medical team looking after me, who I can't thank enough – they are administering the best possible care with expertise, compassion and sensitivity. I'm responding positively to their excellent treatment, and feeling well.' Stage four prostate cancer can mean that the cancer has spread into different parts of the body including nearby body organs, such as the back passage or bladder, nearby lymph nodes and other parts of the body outside the pelvis, such as the bones, lungs or liver, according to the Cancer Research UK website. 'I'm blessed to be fortified by the monumental love and support of my wife, family and close friends', Murnaghan said. 'Needless to say my message to all men over 50, in high risk groups, or displaying symptoms, is get yourself tested and campaign for routine prostate screening by the NHS.' He also said that he is aiming to take part in Sir Chris Hoy's fundraising charity bike ride in September which will raise awareness and funds for cancer charities across the UK. The Olympian announced he had a terminal diagnosis for prostate cancer in October 2024. Article continues below NHS guidance says men over the age of 50 are at highest risk of developing prostate cancer, but Sir Chris wants to help men get screened earlier. About one in eight men will get prostate cancer in their lifetime, according to the charity Prostate Cancer UK, and the disease often has no symptoms in its earlier stages. A number of high-profile cases of prostate cancer have been reported in recent months, including Joe Biden. Eddie Jordan, Len Goodman and OJ Simpson all recently died with prostate cancer. Demand for the PSA Blood Test - which can detected prostate cancer - has shot up this week, doctors say. Dr Mathew Rogers, Digital Clinician at Medichecks, said: "In October 2024, our prostate-specific antigen (PSA) test hit record sales, with more than twice the usual number of men getting a Medichecks prostate cancer screen. The reason? A certain six-time Olympic gold medallist and national treasure may have had something to do with it. When Sir Chris Hoy revealed his diagnosis of prostate cancer, it pushed men to take their health into their own hands. His announcement raised awareness on a scale that only the power of the media could achieve. "Despite the vulnerable situation of having a very private and shocking diagnosis thrown into the spotlight, Hoy used the opportunity to start a national conversation, advocating for men's health and resonating with millions. "With the resilient and positive mindset so many cancer patients possess, Hoy inspired millions of men to take proactive steps towards looking after their health, such as booking PSA tests. The fact he didn't have symptoms highlighted the importance of early detection, and his celebrity status has even prompted the government to consider lowering the screening age for prostate cancer. "Now, Dermot Murnaghan, the 67-year-old announced on social media his diagnosis, saying he is 'responding positively' to treatment and 'feeling well'." Article continues below Medickceks said it had seen a rapid surge in people ordering the PSA check this week. Healthy cells in the prostate make a protein known as prostate-specific antigen, or PSA, a major protein present in semen. PSA can be detected using a blood test, and is commonly used to detect prostate cancer, as high levels can sometimes be a sign of cancer. While a high level of PSA can indicate cancer, there is no generally accepted 'normal' PSA level. The reading differs from person to person, and, as your prostate grows in size with age, the amount of PSA released also tends to increase with age.
